Globally, millions of tons of sugar alcohol products are consumed annually, widely used in food, pharmaceuticals, and daily chemicals. Current production methods are highly dependent on chemical synthesis, which suffers from poor selectivity and generates large amounts of low-value by-products. Meanwhile, many sugar alcohol products are affected by unstable raw material supply, leading to significant fluctuations in production costs.

Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE: 300760), China's largest medical device company and #23 globally by revenue, has filed a draft prospectus for an H-share listing on the Hong Kong Stock Exchange. The move comes amid a strategic pivot toward international markets, which now account for 53% of FY2025 revenue, offsetting a 23% domestic revenue decline. Despite a 9.4% year-over-year drop in total revenue to RMB 33.28 billion and a 28% fall in net profit to RMB 8.45 billion, Mindray maintained robust R&D investment at 10.8% of revenue and generated RMB 10.14 billion in operating cash flow. The IPO aims to bolster its global brand, support M&A initiatives, and align capital structure with its increasingly international business footprint.

On May 11, 2025, Sino Biopharm announced that its subsidiary CHIATAI TIANQING has entered an exclusive strategic partnership with GlaxoSmithKline (GSK) to accelerate the commercialization of bepirovirsen, a first-in-class antisense oligonucleotide (ASO) therapy with triple mechanism of action, in mainland China. CHIATAI TIANQING will manage import, distribution, hospital access, and all promotional activities, recognizing 100% of sales revenue, while GSK remains the Marketing Authorization Holder responsible for regulatory, quality, and global medical strategy. The initial term is 5.5 years, extendable by mutual agreement. Bepirovirsen, submitted for Chinese marketing approval in March 2026 and granted priority review, demonstrated significant functional cure rates in Phase III B-Well trials and could become the first finite-duration therapy to achieve functional cure for chronic hepatitis B—a disease affecting 75 million people in China and causing over 450,000 annual deaths.

Why do the bronchoscopy robots, developed by two industry giants with top engineering teams and years of effort, have a biopsy rate stuck at around 75%? This made Zhang Jian, an engineer, very curious. He spent months "peeling the onion" and finally clarified the essence of the problem: the first-generation bronchoscopy robot emphasizes "navigation" but lacks "real-time positioning."

Founded in 2020, Immunocan is dedicated to building next‑generation antibody discovery platforms powered by gene‑editing technologies. The company's proprietary MASIRT® (Massive-fragment Across Species In situ Replacement Technology) has achieved three core breakthroughs: leveraging a linear artificial chromosome strategy that significantly increases gene fragment loading capacity; enabling Mb-scale DNA in situ replacement in a single operation, significantly reducing the number of editing cycles;

HJ Science Co., Ltd., a Chengdu-based clinical-stage biotech founded in 2017, has filed for a Hong Kong listing with a pre-money valuation of RMB 2.70 billion. The company focuses on small-molecule drug development across autoimmune, metabolic, and oncology indications, leveraging proprietary platforms including TSD-IAS and a Molecular Glue Technology Payload Platform. Its pipeline features nine programs, including three clinical-stage assets: HJ787 (topical TYK2 inhibitor for atopic dermatitis), HJ178 (oral GLP-1/GIP dual agonist for diabetes and obesity), and HJ891 (oral KRAS G12C inhibitor for NSCLC), with HJ197 in Phase III for hepatocellular carcinoma partnered with Junshi Biosciences. Revenue rose to RMB 13.0 million in 2025 from partnership milestones, while net loss narrowed to RMB 135.1 million. The company holds RMB 331.3 million in total liquidity as of March 2026 and plans to use IPO proceeds to fund late-stage trials and commercialization efforts.

Preliminary statistics from VCBeat tracked 11 financing events in China's healthcare sector between May 6 and 9, 2026 (excluding IPOs and private placements). The period was led by CureGene's RMB 300 million Series C round, followed by Nanochap's RMB 300 million strategic financing round.

Kexing Biopharm's origins predate the wave of innovative drugs in China by more than two decades. Over the course of its development, three key strategic decisions have shaped its current industry position and development direction.

Against this significant favorable policy backdrop, CuraWay Medical's percutaneous interventional surgical robot, with its clear clinical value (improved puncture accuracy, reduced complications, and lower radiation exposure), forms a synergistic advantage with the company's supporting interventional devices. This financing round will significantly accelerate the company's commercialization process, allowing it to seize the first-mover advantage in the market.

The company's core product, Evategrel (CG-0255), is a global first-in-class, next-generation P2Y12 receptor inhibitor available in both intravenous and oral formulations. Utilizing an innovative thiol-hydrolyzing prodrug design, it achieves rapid onset (less than 15 minutes for injection, less than 30 minutes for oral administration) and completely overcomes the "clopidogrel resistance" issue present in approximately 58% of the Chinese population.

Although the number of commercialized brands is increasing, market changes in various subfields differ: In the orthopedics and natural orifice fields, a "even a good tiger can't withstand a pack of wolves" trend is emerging. The combined market share of the top three players (CR3) in these markets as a proportion of the overall market is declining. Orthopedics CR3 decreased from 53% in 2024 to 40% in 2025, while natural orifice CR3 dropped from 89% to 56%.

Kexing Biopharm's origins predate the wave of innovative drugs in China by more than two decades. Over the course of its development, three key strategic decisions have shaped its current industry position and development direction.

Why do the bronchoscopy robots, developed by two industry giants with top engineering teams and years of effort, have a biopsy rate stuck at around 75%? This made Zhang Jian, an engineer, very curious. He spent months "peeling the onion" and finally clarified the essence of the problem: the first-generation bronchoscopy robot emphasizes "navigation" but lacks "real-time positioning."

Against this significant favorable policy backdrop, CuraWay Medical's percutaneous interventional surgical robot, with its clear clinical value (improved puncture accuracy, reduced complications, and lower radiation exposure), forms a synergistic advantage with the company's supporting interventional devices. This financing round will significantly accelerate the company's commercialization process, allowing it to seize the first-mover advantage in the market.

Given that the company already has a stable A-share financing channel and a consistent dividend-paying capability, the decision to proceed with an H-share issuance in Hong Kong typically reflects three considerations: first, to establish an offshore capital vehicle necessary for global business expansion; second, to attract international investors and enhance valuation benchmarks; and third, to meet the capital requirements of potential future major strategic initiatives such as cross-border mergers and acquisitions or overseas factory construction.

If policy reshaped the industry's rules and R&D capabilities drove the industry's transformation, then the capital market has largely determined the pace of development for the innovative drug industry. Over the past decade, with the successive implementation of reforms on the STAR Market and the Hong Kong stock exchange, Chinese innovative drug companies have gradually gained access to financing channels. The capital market, in tandem with industry development, has experienced a full cycle ranging from initial exploration and concentrated capital inflows to deep adjustment.

What has drawn even more market attention is the cornerstone investor lineup. METiS TechBio has secured collective support from international asset managers, international specialized healthcare funds, AI technology funds, state-backed funds, and Chinese public fund giants.

Unlike the previous purely conceptual hype, this wave of increase appears to be well-founded. As annual reports are gradually released, leading CXOs have seen their revenue double, gross margins significantly improve, and orders surge. Although the next day, the sector failed to maintain its strong momentum. However, the growth in performance has led to expectations of an industry recovery.

HH160 is a hexavalent trispecific antibody developed by Huahui Health based on its proprietary PolyBoost™ multispecific antibody platform. Constructed on a bevacizumab backbone, the molecular structure incorporates Fc-silencing modifications that eliminate antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), thereby reducing immune-related inflammatory responses.

As commercialization accelerates, Mabwell's strategic focus has naturally extended from the local market to a global footprint. In the biosimilar segment, the company places particular emphasis on emerging markets and countries along the Belt and Road, adopting a "licensing plus local partnership" model, under which Mabwell grants its partners in target markets the rights to register, fill and finish, sell, and promote its products, leveraging their regulatory capabilities and commercial networks to rapidly achieve market entry and increase the share of overseas revenue.

On May 11, 2025, Sino Biopharm announced that its subsidiary CHIATAI TIANQING has entered an exclusive strategic partnership with GlaxoSmithKline (GSK) to accelerate the commercialization of bepirovirsen, a first-in-class antisense oligonucleotide (ASO) therapy with triple mechanism of action, in mainland China. CHIATAI TIANQING will manage import, distribution, hospital access, and all promotional activities, recognizing 100% of sales revenue, while GSK remains the Marketing Authorization Holder responsible for regulatory, quality, and global medical strategy. The initial term is 5.5 years, extendable by mutual agreement. Bepirovirsen, submitted for Chinese marketing approval in March 2026 and granted priority review, demonstrated significant functional cure rates in Phase III B-Well trials and could become the first finite-duration therapy to achieve functional cure for chronic hepatitis B—a disease affecting 75 million people in China and causing over 450,000 annual deaths.

In October 2023, Alebund acquired the exclusive commercial rights in China for Roche's long-acting erythropoietin MIRCERA® (AP601). This global first-in-class long-acting erythropoietin (EPO), administered once monthly, is indicated for the treatment of CKD-related anemia. After being included in the National Reimbursement Drug List (NRDL) in 2024, it experienced rapid uptake, contributing RMB 30.556 million in revenue in 2025, accounting for 100% of total revenue.

HH160 is a hexavalent trispecific antibody developed by Huahui Health based on its proprietary PolyBoost™ multispecific antibody platform. Constructed on a bevacizumab backbone, the molecular structure incorporates Fc-silencing modifications that eliminate antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), thereby reducing immune-related inflammatory responses.

For pharmaceutical companies, the significance of the CTP is even more direct: securing a spot provides the most authoritative endorsement for a pipeline asset, after which subsequent clinical advancement, out-licensing deals, and commercial rollout become much easier, sometimes even triggering a surge in stock price. As a result, many companies make it their primary goal to get their assets into the CTP. Historically, CTP slots have been locked down by MNCs.

As an investigational human monoclonal antibody targeting CD38, felzartamab possesses significant clinical potential due to its unique mechanism of action. It selectively depletes CD38-positive plasma cells, blocking the generation of pathogenic antibodies at the source.

However, these synergistic integration efforts have not reached the ideal state. Trividia and PTS have often experienced performance losses and goodwill impairment, affecting Sinocare's profits. For example, in 2019, the business operations of PTS were impacted, resulting in goodwill impairment of 25 to 50 million RMB; Trividia's operating loss impacted Sinocare's investment income by approximately -60 to -75 million RMB. In 2020, both PTS and Trividia were in a state of operating loss. In 2021, Trividia continued to incur losses; in 2023, Trividia faced operating losses and goodwill impairment.

Multinational pharmaceutical companies are now capturing high ground in the radiopharmaceutical space through a dual strategy of deep collaboration plus capacity pre-positioning — securing both cutting-edge technologies and project pipelines while also establishing localized production of scarce radionuclides ahead of time. The global radiopharmaceutical competition has formally entered a stage of value-chain positioning battles.

3M Corp. Achieves Better-than-Expected Performance in Fiscal Year 2025 After Spinning Off Healthcare Business into Independently Listed Solventum

United Imaging has showcased more imaging information from uCT Ultima at its booth this year, combined with unique rendering technology, which indeed elevates imaging and performance to a new level. In terms of commercialization, uCT Ultima has been installed and officially put into clinical use at West China Xiamen Hospital, Sichuan University, and Huaxi Xiamen Hospital. Regarding clinical validation, the on-site staff stated that more than 4,000 clinical scans have been completed in total.

Gilead Sciences, Not Content as HIV Leader, Shows Strong Ambition in Oncology. On April 9, it secured global development rights for KT-200. The original developer, Kymera, will receive a $45 million milestone payment and is eligible for substantial total payments and tiered royalties. On the 100th day of 2026, Gilead made its fourth move, with a potential total deal value of approximately $15.725 billion, including the acquisition of CAR-T company Arcellx, the merger with Ouro Medicines, and the purchase of Germany's next-generation ADC company Tubulis Technologies. KT-200, the subject of this transaction, is the world’s first oral molecular glue degrader targeting CDK2, which selectively eliminates CDK2, a key driver of tumor growth, offering a more precise, safe, and effective oral treatment option for cancers dependent on CDK2 activity. Preclinical tests have shown strong activity, potential for brain penetration, and good safety.